Dr. Reddy's Laboratories

We are thrilled to announce that Dr. Reddy's Laboratories has been honored with multiple accolades at the Express Pharma Excellence Awards 2025. These prestigious awards recognize our excellence in three key categories: ? ? Export Powerhouse (FY24) Finished Formulations:?Celebrating our global reach and impact in delivering high-quality finished pharmaceutical products. ? Market Trailblazers:?Acknowledging our innovative strategies and leadership in the pharmaceutical market. ? Export Powerhouse (FY24) APIs & Intermediates:?Highlighting our strength in exporting active pharmaceutical ingredients and intermediates worldwide. ? These awards are a testament to our unwavering commitment to innovation, quality, and excellence in the pharmaceutical industry. We are incredibly proud of our dedicated team whose hard work and passion have made these achievements possible. Thank you to @Express Pharma for recognizing our efforts and to our partners, customers, and stakeholders for their continuous support. Together, we are making a difference in global healthcare. ? #DrReddys #PharmaExcellence #Innovation #Healthcare #ExpressPharmaAwards #Teamwork #GlobalImpact

Live from BioAsia 2025! ?? A heartfelt gratitude to Telangana Lifesciences, Hon’ble Chief Minister ???????? ??. ?????????????? ??????????, and Hon’ble IT Minister ???????? ??. ?????????????? ???????? for their unwavering support to the innovative pharma services sector. Their commitment to innovation, investment, and global collaboration is paving the way for transformative advancements in healthcare. At BioAsia 2025, our ?????????? ?????????????????? ?????? ?????????????????? ?????????????? are excited to connect and explore how Aurigene services can accelerate your molecule’s journey from lab to market. ?? Please drop by our stand or write to [email protected] to schedule a meeting with our experts. Let’s drive innovation forward together! Akhil Ravi Kapil Choudhury Amit Jogi Ruksana Khatoon Tania Dey Dr. Rashmi Gupta Dr. Reddy's Laboratories #BioAsia2025 #Innovation #PharmaServices #Biologics #SmallMolecules #AurigeneServices

Driving growth and efficiency through digital innovation and strategic capabilities. Phani Mitra B, Global CIO & CDO, Dr. Reddy’s Laboratories, discusses how organic growth is achieved by improving efficiency in the value chain, focusing on digital ecosystem initiatives, and building new capabilities. The power of AI and Gen AI is leveraged to accelerate purpose-driven value creation and streamline operations for better scalability. Shakthi M Nagappan Telangana Lifesciences Phani Mitra B Dr. Reddy's Laboratories #BioAsia2025 #CatalystsOfChange #LifeSciencesSummit #GlobalHealthcare

Speed, efficiency, and innovation will define the next phase of pharma outsourcing. Akhil Ravi, CEO, Aurigene Pharmaceutical Services, India, highlights the need to boost R&D productivity, leverage automation and AI, and solve key challenges in talent and raw material sourcing. Strengthening India's capabilities will be critical to long-term success in the global market. Shakthi M Nagappan Telangana Lifesciences Akhil Ravi Aurigene Pharmaceutical Services Limited #BioAsia2025 #CatalystsOfChange #LifeSciencesSummit #GlobalHealthcare

Innovation in the life sciences is a dynamic journey that requires both risk-taking and resilience. G.V. Prasad, Co-Chairman & Managing Director, Dr. Reddy's Laboratories, India, emphasizes the importance of incremental innovation, attracting talent, and building visibility in a nascent ecosystem. While AI is a game-changer, we still need a deep scientific foundation for it to reach its full potential. He also highlights the challenges of generic product development and clinical trials and stresses the importance of embracing failure as part of the innovation process. India’s capacity to innovate for India and then take it global is crucial for long-term success in the global pharmaceutical landscape. India’s innovation ecosystem must continue to evolve, learn from China’s robust model, and focus on creating premium innovation for both the local and global markets. Shakthi M Nagappan Telangana Lifesciences Prasad G V Dr. Reddy's Laboratories #BioAsia2025 #CatalystsOfChange #LifeSciencesSummit #GlobalHealthcare

We are pleased to welcome Cristina Diaz Marin into the Dr. Reddy’s family as Head – Regulatory & Government Affairs, Consumer Health (newly acquired global portfolio of?Nicotinell). ? Cristina will be based in Basel. A seasoned Regulatory Affairs professional, Cristina has worked with multiple leading pharmaceutical companies in various therapy areas. We look forward to Cristina’s leadership in helping us build a strong consumer health journey. ? #GoodHealthCantWait?#WeAreDrReddys

Our teams are preparing for DCAT (Drug, Chemical & Associated Technologies Association) Week. This event is a great opportunity to network, share insights, and delve into the latest innovations in the pharmaceutical and chemical industries. We're looking forward to discussing how we can contribute to your sustainable supply chain. If you're attending, let's meet! #DCAT #WeAreDrReddys #GoodHealthCantWait

One of the pillars of our social impact work is climate-proofing of livelihoods of small and marginal farmers given the increasingly adverse impact of climate change, by nudging them to adopt climate-friendly technologies and farming practices. Soil health is the foundation of food security, environmental sustainability, and human well-being. Soil is more than just dirt — it is a living, breathing ecosystem that sustains life. Our new Soil Testing Research Centre in Hyderabad recognises the ‘One Health’ philosophy - the interconnectedness of soil, plant, and human health. We invited Suman S., Head of Climate Action and Rural Livelihoods at Dr Reddy's Foundation to tell us more. Click to read his blog.

Pleased to announce our collaboration with Henlius to make HLX15, the daratumumab biosimilar candidate, available to patients in the U.S. and Europe, in subcutaneous as well as intravenous formulations. HLX15 is being developed as a biosimilar of Darzalex?? & Darzalex Faspro??, which are indicated for the treatment of multiple myeloma. Over the years, we have created a portfolio of biosimilar products that are being marketed in several emerging markets. The launch of our pegfilgrastim through our collaborator in the U.S. in 2023, and bevacizumab in the United Kingdom last year marked the start of our biosimilars journey in regulated markets. Last year, we also signed a collaboration with Alvotech for the commercialisation of their denosumab biosimilar in the U.S. and Europe. This latest collaboration with Henlius further progresses our regulated markets journey in biosimilars. Oncology has been a top focus therapy area for us. We look forward to leveraging our strong commercial capabilities in these markets to ensure patients receive access to best-in-class therapies and affordable treatment options. With each product, we continue our endeavour to drive access and affordability of innovative products, and our journey towards serving over 1.5 billion patients by 2030. To read more, please visit: https://lnkd.in/dV3_ysEh #WorldCancerDay #GoodHealthCantWait #WeAreDrReddys #DrReddysBiologics #SDG3 (promoting good health and well-being)

On ?????????? ???????????? ??????, we at ???????????????? ???????????????????????????? ???????????????? reaffirm our commitment to pioneering advanced therapies and driving progress in the fight against cancer. Together, we can create a future free from cancer. ????? #WorldCancerDay #CancerResearch #CancerFreeTomorrow #Aurigene?